Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 5, 2005 - Issue 4
Submit an article Journal homepage
113
Views
36
CrossRef citations to date
0
Altmetric
Review

Local delivery of antineoplastic agents by controlled-release polymers for the treatment of malignant brain tumours

Shaan M Raza The Johns Hopkins University School of Medicine, Department of Neurological Surgery, 600 N. Wolfe Street, Meyer 7-113, Baltimore, MD 21287, USA. [email protected]
,
Gustavo Pradilla The Johns Hopkins University School of Medicine, Department of Neurological Surgery, 600 N. Wolfe Street, Meyer 7-113, Baltimore, MD 21287, USA. [email protected]
,
Federico G Legnani The Johns Hopkins University School of Medicine, Department of Neurological Surgery, 600 N. Wolfe Street, Meyer 7-113, Baltimore, MD 21287, USA. [email protected]; Ospedale San Gerardo, Monza, Italy
,
Quoc Anh Thai The Johns Hopkins University School of Medicine, Department of Neurological Surgery, 600 N. Wolfe Street, Meyer 7-113, Baltimore, MD 21287, USA. [email protected]
,
Alessandro Olivi The Johns Hopkins University School of Medicine, Department of Neurological Surgery, 600 N. Wolfe Street, Meyer 7-113, Baltimore, MD 21287, USA. [email protected]; The Johns Hopkins University School of Medicine, Department of Ophthalmology, Baltimore, Maryland, USA
,
Jon D Weingart The Johns Hopkins University School of Medicine, Department of Neurological Surgery, 600 N. Wolfe Street, Meyer 7-113, Baltimore, MD 21287, USA. [email protected]; The Johns Hopkins University School of Medicine, Department of Oncology, Baltimore, Maryland, USA
&
Henry Brem The Johns Hopkins University School of Medicine, Department of Neurological Surgery, 600 N. Wolfe Street, Meyer 7-113, Baltimore, MD 21287, USA. [email protected]
 show all
Pages 477-494 | Published online: 22 Apr 2005

Bibliography

  • LEGLER JM, RIES LA, SMITH MA et al.: Cancer surveillance series [corrected]: brain and other central nervous system cancers: recent trends in incidence and mortality. J. Natl. Cancer Inst. (1999) 91(16):1382–1390.
  • ROSTOMILY R, KELES GE, BERGER MS: Radical surgery in the management of low-grade and high-grade gliomas. Baillieres Clin. Neurol (1996) 5(2):345–369.
  • BURTON EC, PRADOS MD: Malignant gliomas. Curr. Treat. Options Oncol (2000) 1(5):459–468.
  • CASTRO MG, COWEN R, WILLIAMSON IK et al.: Current and fitture strategies for the treatment of malignant brain tumors. Pharmacol. Ther. (2003) 98(1):71–108.
  • PARNEY IF, CHANG SM: Current chemotherapy for glioblastoma. Cancer J. (2003) 9(3):149–156.
  • GURNEY JG, KADAN-LOTTICK N: Brain and other central nervous system tumors: rates, trends, and epidemiology. Curr. Opin. Oncol (2001) 13(3):160–166.
  • BARKER FG 2"d, CHANG SM, GUTIN PH et al.: Survival and functional status after resection of recurrent glioblastoma multiforme. Neurosurgery (1998) 42(4):709–720; discussion 720–703.
  • MOHAN DS, SUH JH, PT-JAN JL, KUPELIAN PA, COHEN BH, BARNETT GH: Outcome in elderly patients undergoing definitive surgery and radiation therapy for supratentorial glioblastoma multiforme at a tertiary care institution. Int. J. Radiat. Oncol Biol. Phys. (1998) 42(5):981–987.
  • HENTSCHEL SJ, SAWAYA R: Optimizing outcomes with maximal surgical resection of malignant gliomas. Cancer Control (2003) 10(2):109–114.
  • LESNIAK MS, BREM H: Targeted therapy for brain tumours. Nat. Rev. Drug Discov. (2004) 3(6):499–508.
  • RAUTIOA J, CHIKHALE PJ: Drug delivery systems for brain tumor therapy. Curr. Pharm. Des. (2004) 10(12):1341–1353.
  • GHERSI-EGEA JF, LEININGER-MULLER B, CECCHELLI R, FENSTERMACHER JD: Blood-brain interfaces: relevance to cerebral drug metabolism. Toxicol Lett. (1995) 82–83:645–653.
  • KUSUHARA H, SUGIYAMA Y: Efflux transport systems for drugs at the blood-brain barrier and blood-cerebrospinal fluid barrier (Part 2). Drug Discov. Today (2001) 6(4):206–212.
  • KUSUHARA H, SUGIYAMA Y: Efflux transport systems for drugs at the blood-brain barrier and blood-cerebrospinal fluid barrier (Part 1). Drug Discov. Today (2001) 6(3):150–156.
  • TAMARGO RJ, BREM H: Drug delivery to the central nervous system: a review. Neurosurg Q., (1992) 2(4):259–279.
  • ABBOTT NJ, ROMERO IA: Transporting therapeutics across the blood-brain barrier. Mol Med. Today (1996) 2(3):106–113.
  • GRIEG NH: Opitimizing drug delivery to brain tumors. Cancer Treat. Rev. (1987) 14(1):1–28.
  • CHIN HW, YOUNG AB, MARUYAMAY: Survival response of malignant gliomas to radiotherapy with or without BCNU or methyl-CCNU chemotherapy at the University of Kentucky Medical Center. Cancer Treat. Rep. (1981) 65(1-2):45–51.
  • KORNBLITH PL, WALKER M: Chemotherapy for malignant gliomas. Neurosurg (1988) 68(1):1–17.
  • MEDICAL RESEARCH COUNCIL BRAIN TUMOR WORKING PARTY: Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial. J. Clin. Oncol (2001) 19(2):509–518.
  • LOO TL, DION R1,, DIXON RL, RALL DP: The antitumor agent, 1,3-bis(2-chloroethyl)-1-nitrosourea. j Pharm. Sci. (1966) 55:492–497.
  • PROKAI L, PROKAI-TATRAI K, BODOR N: Targeting drugs to the brain by redox chemical delivery systems. Med. Res. Rev. (2000) 20(5):367–416.
  • WILLIAMS PC, HENNER WD, ROMAN-GOLDSTEIN S et al.: Toxicity and efficacy of carboplatin and etoposide in conjunction with disruption of the blood-brain barrier in the treatment of intracranial neoplasms. Neurosurgery (1995) 37(1):17–28.
  • CHEN MY, LONSER RR, MORRISON PF, GOVERNALE LS, OLDFIELD EH: Variables affecting convection-enhanced delivery to the striatum: a systematic examination of rate of infusion, cannula size, infusate concentration, and tissue-cannula sealing time./ Neurosurg. (1999) 90(2):315–320.
  • DEGEN JW, WALBRIDGE S, VORTMEYER AO, OLDFIELD EH, LONSER RR: Safety and efficacy of convection-enhanced delivery of gemcitabine or carboplatin in a malignant glioma model in rats. J. Neurosurg. (2003) 99(5):893–898.
  • HAMILTON JF, MORRISON PF, CHEN MY et al.: Heparin coinfusion during convection-enhanced delivery (CED) increases the distribution of the glial-derived neurotrophic factor (GDNF) ligand family in rat striatum and enhances the pharmacological activity of neurturin. Exp. Neurol (2001) 168(1):155–161.
  • LASKE DW, MORRISON PF, LIEBERMAN DM et al.: Chronic interstitial infitsion of protein to primate brain: determination of drug distribution and clearance with single-photon emission computerized tomography imaging. J. Neurosurg (1997) 87(4):586–594.
  • LIEBERMAN DM, LASKE DW, MORRISON PF, BANKIEWICZ KS, OLDFIELD EH: Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion. J. Neurosurg (1995) 82(0:1021–1029.
  • BOBO RH, LASKE DW, AKBASAK A, MORRISON PF, DEDRICK RL, OLDFIELD EH: Convection-enhanced delivery of macromolecules in the brain. Proc. Natl Acad. Sci. USA (1994) 91(6):2076–2080.
  • LIDAR Z, MARDOR Y, JONAS T et aL: Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a Phase I/II clinical study. Neurosurg. (2004) 100(3):472–479.
  • REN H, BOULIKAS T, LUNDSTROM K, SOLING A, WARNKE PC, RAINOV NG: Immunogene therapy of recurrent glioblastoma multiforme with a liposomally encapsulated replication-incompetent Semliki forest virus vector carrying the human interleukin-12 gene-a Phase I/II clinical protocol. J. NeurooncoL (2003) 64(1-2):147–154.
  • SAMPSON JH, AKABANI G, ARCHER GE et al.: Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. J. Neurooncol (2003) 65(1):27–35.
  • VOGES J, RESZKA R, GOSSMANN A et al.: Imaging-guided convection-enhanced delivery and gene therapy of glioblastoma. Ann. NeuroL (2003) 54(4):479–487.
  • WEBER FW, FLOETH F, ASHER A et al.: Local convection enhanced delivery of IL4-Pseu,clomonas exotoxin (NBI-3001) for treatment of patients with recurrent malignant glioma. Acta Neurochir. Suppl. (2003) 88:93–103.
  • MARDOR Y, ROTH Y, LIDAR Z et cll.: Monitoring response to convection-enhanced taxol delivery in brain tumor patients using diffusion-weighted magnetic resonance imaging. Cancer Res. (2001) 61(13):4971–4973.
  • WEBER F, ASHER A, BUCHOLZ R et cll.: Safety, tolerability, and tumor response of IL4-Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma. Neuroonco/. (2003) 64(1–2):125–137.
  • LANGER R: New methods of drug delivery. Science (1990) 249(4976):1527–1533.
  • LANGER R, FOLKMAN J: Polymers for the sustained release of proteins and other macromolecules. Nature (1976) 263(5580):797–800.
  • URTTI A. ROUHIAINEN H, KARA T, SAANO V: Controlled ocular timolol delivery: systemic absorption and intraocular pressure effects in humans. Pharm. Res. (1994) 11(9):1278–1282.
  • YUE IC, POFF J, CORTES ME et al.: A novel polymeric chlorhexidine delivery device for the treatment of periodontal disease. Biomaterieds (2004) 25(17):3743–3750.
  • FRIEND DR: Transdermal delivery of contraceptives. Crit. Rev. Ther. Drug Carrier Syst. (1990) 7(2):149–186.
  • LANGER RS, WISE DL: Medical Applications of Controlled Release. Langer RS, Wise DL (Eds), CRC Press, Boca Raton, FL, USA (1984):2v.
  • BRADY JM, CUTRIGHT DE, MILLER RA, BARRISTONE GC: Resorption rate, route, route of elimination, and ultrastructure of the implant site of polylactic acid in the abdominal wall of the rat. J. Biomed. Mater. Res. (1973) 7(2):155–166.
  • FRAZZA EJ, SCHMITT EE: A new absorbable suture. J. Biomed. Mater. Res. (1971) 5(2):43–58.
  • KONG Q, KLEINSCHMIDT-DEMASTERS BK, LILLEHEI KO: Intralesionally implanted cisplatin cures primary brain tumor in rats. Surg Oncol (1997) 64(4):268–273.
  • LILLEHEI KO, KONG Q, WITHROW SJ, KLEINSCHMIDT-DEMASTERS BK: Efficacy of intralesionally administered cisplatin-impregnated biodegradable polymer for the treatment of 9L gliosarcoma in the rat. Neurosurgery (1996) 39(6):1191–1199.
  • LEWIS DH: Controlled release of bioactive agents from lactide/glycolide polymers. In: Biodegradable Polymers as Drug Delivery Systems. Chasin M, Langer R (Eds), Marcel Dekker, New York, NY, USA (1990):1–41.
  • SPENLEHAUER G, VERT M, BENOIT JP, BODDAERT A: In vitro and in vivo degradation of poly(D,L lactide/ glycolide) type microspheres made by solvent evaporation method. Biomaterieds (1989) 10(8):557–563.
  • BENOIT JP, FAISANT N, VENTER-JULIENNE MC, MENEI P: Development of microspheres for neurological disorders: from basics to clinical applications. J. Control. Release (2000) 65(1-2):285–296.
  • LAMPRECHT A, UBRICH N, YAIVIAMOTO H et aL Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease. J. PharmacoL Exp. Ther. (2001) 299(2):775–781.
  • SATO H, WANG YM, ADACHI I, HORIKOSHI I: Pharmacokinetic study of taxol-loaded poly(lactic-co-glycolic acid) microspheres containing isopropyl myristate after targeted delivery to the lung in mice. Biol. Pharm. Bull. (1996) 19(12):1596–1601.
  • SUGIYAMA T, KUMAGAI S, NISHIDAT et al.: Experimental and clinical evaluation of cisplatin-containing microspheres as intraperitoneal chemotherapy for ovarian cancer. Anticancer Res. (1998) 18(4B):2837–2842.
  • WILLIAMS RC, PAQUETTE DW, OFFENBACHER S et al.: Treatment of periodontitis by local administration of minocycline microspheres: a controlled trial. J. Periodontol. (2001) 72(11):1535–1544.
  • MENEI P, BENOIT JP, BOISDRON-CELLE M, FOURNIER D, MERCIER P, GUY G: Drug targeting into the central nervous system by stereotactic implantation of biodegradable microspheres. Neurosurgery (1994) 34(6):1058–1064.
  • BREM H, LANGER R: Polymer-based drug delivery to the brain. Sci. Med. (1996) July/August:52–61.
  • LEONG KW, BROTT BC, LANGER R: Bioerodible polyanhydrides as drug-carrier matrices. I: Characterization, degradation, and release characteristics. J. Biomed. Mater. Res. (1985) 19(8):941–955.
  • CHASIN M, DOMB A, RON E: Polyanhydrides as drug delivery systems. In: Biodegradable Polymers as Drug Delivery Systems. Chasin M, Langer R (Eds), Marcel Dekker, New York, NY, USA (1990):43–70.
  • BINDSCHAEDLER C, LEONG K, MATHIOWITZ E, LANGER R: Polyanhydride microsphere formulation by solvent extraction. J. Pharm. Sci. (1988) 77(8):696–698.
  • HOWARD MA 3rd, GROSS A, GRADY MS et al.: Intracerebral drug delivery in rats with lesion-induced memory deficits. J. Neurosurg. (1989) 71(1):105–112.
  • LEONG KW, KOST J, MATHIOWITZ E,LANGER R: Polyanhydrides for controlled release of bioactive agents. Biomaterials (1986) 7(5):364–371.
  • MATHIOWITZ E, SALTZMAN M, DOMB A: Polyanhydride microspheres as drug carriers. II. Microencapsulation by solvent removal. J. And Polym. Sci. (1988) 35:755–774.
  • BREM H, KADER A, EPSTEIN JI et al.: Biocompatibility of a biodegradable, controlled-release polymer in the rabbit brain. SeL Cancer Ther. (1989) 5(2):55–65.
  • LANGER R, BREM H, TAPPER D: Biocompatibility of polymeric delivery systems for macromolecules. J. Biomed. Mater. Res. (1981) 15(2):267–277.
  • TAMARGO RJ, EPSTEIN JI, REINHARD CS, CHASIN M, BREM H: Brain biocompatibility of a biodegradable, controlled-release polymer in rats. Biomed. Mater. Res. (1989) 23(2):253–266.
  • BREM H, TAMARGO RJ, OLIVI A et ell.: Biodegradable polymers for controlled delivery of chemotherapy with and without radiation therapy in the monkey brain. Neurosurg. (1994) 80(2):283–290.
  • SHIEH L, TAIVIADA J, CHEN I, PANG J, DOMB A, LANGER R: Erosion of a new family of biodegradable polyanhydrides. Biomed. Mater. Res. (1994) 28(12):1465–1475.
  • TABATA Y, LANGER R: Polyanhydride microspheres that display near-constant release of water-soluble model drug compounds. Pharm. Res. (1993) 10(3):391–399.
  • TABATA Y, GUTTA S, LANGER R: Controlled delivery systems for proteins using polyanhydride microspheres. Pharm. Res. (1993) 10(4):487–496.
  • JUDY KD, OLIVI A. BUAHIN KG et al.: Effectiveness of controlled release of a cyclophosphamide derivative with polymers against rat gliomas. J. Neurosurg. (1995) 82(3):481–486.
  • OLIVI A, EWEND MG, UTSUKI T et aL: Interstitial delivery of carboplatin via biodegradable polymers is effective against experimental glioma in the rat. Cancer Chemother. PharmacoL (1996) 39(1-2):90–96.
  • SHIKANI AH, EISELE DW, DOMB AJ: Polymer delivery of chemotherapy for squamous cell carcinoma of the head and neck. Arch. OtolaryngoL Head Neck Surg. (1994) 120(11):1242–1247.
  • GOLUMBEK PT, AZHARI R, JAFFEE EM et al.: Controlled release, biodegradable cytokine depots: a new approach in cancer vaccine design. Cancer Res. (1993) 53(24):5841–5844.
  • GABIZON AA: Liposomal anthracyclines. HematoL OncoL Clin North Am. (1994) 8(2):431–450.
  • HIRAKAWA W, KADOTA K, ASAKURAT et al.: [Local chemotherapy for malignant brain tumors using methotrexate-containing fibrin glue]. Gan To Kagaku Ryoho (1995) 22(6):805–809.
  • RINGKJOB R: Treatment of intracranial gliomas and metastatic carcinomas by local application of cytostatic agents. Acta NeuroL Scand. (1968) 44(3):318–322.
  • RAMA B, MANDEL T, JANSEN J, DINGELDEIN E, MENNEL HD: The intraneoplastic chemotherapy in a rat brain tumour model utilizing methotrexate-polymethylmethacrylate-pellets. Acta Neurochir. (1987) 87(1-2):70–75.
  • ODA Y, TOKURIKI Y, TSUDA E, HANDA H, KIELER J: Trial of anticancer pellet in malignant brain tumours; 5 FU and urokinase embedded in silastic. Acta Neurochir. SuppL (1979) 28(2):489–490.
  • PARDRIDGE WM: Vector-mediated drug delivery to the brain. Adv. Drug Deli v. Rev. (1999) 36(2-3):299–321.
  • GREEN SB, BYAR DP, WALKER MD et al.: Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. Cancer Treat. Rep. (1983) 67(2):121–132.
  • WALKER MD, GREEN SB, BYAR DP et al.: Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl. J. Med. (1980) 303(23):1323–1329.
  • GROSSMAN SA, REINHARD C, COLVIN OM et al.: The intracerebral distribution of BCNU delivered by surgically implanted biodegradable polymers. J. Neurosurg-. (1992) 76(4):640–647.
  • FUNG LK, EWEND MG, SILLS A et aL:Pharmacokinetics of interstitial delivery of carmustine, 4-hydroperoxycyclophosphamide, and paclitaxel from a biodegradable polymer implant in the monkey brain. Cancer Res. (1998) 58(4):672–684.
  • TAMARGO RJ, MYSEROS JS, EPSTEIN JI, YANG MB, CHASIN M, BREM H: Interstitial chemotherapy of the 9L gliosarcoma: controlled release polymers for drug delivery in the brain. Cancer Res. (1993) 53(2):329–333.
  • GALICICH JH, SUNDARESAN N, THALER HT: Surgical treatment of single brain metastasis. Evaluation of results by computerized tomography scanning. J. Neurosurg-. (1980) 53(1):63–67.
  • BREM H, MAHALEY MS JR, VICK NA et al.: Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. j Neurosurg-. (1991) 74(3):441–446.
  • BREM H, PIANTADOSI S, BURGER PC et al.: Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet (1995) 345(8964):1008–1012.
  • BREM H, EWEND MG, PIANTADOSI S, GREENHOOT J, BURGER PC, SISTI M: The safety of interstitial chemotherapy with BCNU-loaded polymer followed by radiation therapy in the treatment of newly diagnosed malignant gliomas: Phase I trial. J. Neuroonca (1995) 26(2):111–123.
  • VALTONEN S, TIMONEN U, TOIVANEN P et al.: Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study. Neurosurgery (1997) 41(1):44–48.
  • WESTPHAL M, HILT DC, BORTEY E et al.: A Phase III trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-oncoL (2003) 5(2):79–88.
  • SIPOS EP, TYLER B, PIANTADOSI S, BURGER PC, BREM H: Optimizing interstitial delivery of BCNU from controlled release polymers for the treatment of brain tumors. Cancer Chemother. PharmacoL (1997) 39(5):383–389.
  • OLIVI A, GROSSMAN SA, TATTERS et al.: Dose escalation of carmustine in surgically implanted polymers in patients with recurrent malignant glioma: a New Approaches to Brain Tumor Therapy CNS Consortium trial. J. Clin. OncoL (2003) 21(9):1845–1849.
  • SILBER JR, BOBOLA MS, GHATAN S, BLANK A, KOLSTOE DD, BERGER MS: 06-methylguanine-DNA methyltransferase activity in adult gliomas: relation to patient and tumor characteristics. Cancer Res. (1998) 58(5):1068–1073.
  • PEGG AE, BOOSALIS M, SAMSON L et aL: Mechanism of inactivation of human 06-alkylguanine-DNA alkyltransferase by 06-benzylguanine. Biochemistry (1993) 32(45):11998–12006.
  • FRIEDMAN HS, KEIR S, PEGG AE et al.: 06-benzylguanine-mediated enhancement of chemotherapy. MoL Cancer Ther. (2002) 1(11):943–948.
  • SCHOLD SC JR, KOKKINAKIS DM, CHANG SM et al.: 06-benzylguanine suppression of 06-alkylguanine-DNA alkyltransferase in anaplastic gliomas. Neuro-oncoL (2004) 6(1):28–32.
  • RHINES LD, SAMPATH P, DOLAN ME, TYLER BM, BREM H, WEINGART J: 06-benzylguanine potentiates the antitumor effect of locally delivered carmustine against an intracranial rat glioma. Cancer Res. (2000) 60(22):6307–6310.
  • CAHAN MA, WALTER KA, COLVIN OM, BREM H: Cytotoxicity of taxol in vitro against human and rat malignant brain tumors. Cancer Chemother. Pharmacol. (1994) 33(5):441–444.
  • KLECKER R, JAMIS-DOW C, EGORIN M: Distribution and metabolism of 3-H Taxol in the rat (abstract). Proc. Am. Assoc. Cancer Res. (1992) 34:381.
  • WALTER KA, CAHAN MA, GUR A et al.: Interstitial taxol delivered from a biodegradable polymer implant against experimental malignant glioma. Cancer Res. (1994) 54(8):2207–2212.
  • LI KW, DANG W, TYLER BM et ell.: Polilactofate microspheres for Paclitaxel delivery to central nervous system malignancies. Clin. Cancer Res. (2003) 9(9):3441–3447.
  • REECE DE, BARNETT MJ, CONNORS JM et aL: Treatment of multiple myeloma with intensive chemotherapy followed by autologous BMT using marrow purged with 4-hydroperoxycyclophosphamide. Bone Marrow Transplant. (1993) 11(2):139–146.
  • LEMOLI RM, GASPARETTO C, SCHEINBERG DA, MOORE MA, CLARKSON BD, GULATI SC: Autologous bone marrow transplantation in acute myelogenous leukemia: in vitro treatment with myeloid-specific monoclonal antibodies and drugs in combination. Blood (1991) 77(8):1829–1836.
  • CHABNER BA, COLLINS JM: Cancer Chemotherapy: Principles and Practice. Chabner BA, Collins JM (Eds), JB Lippencott, Philadelphia, PA, USA (1990).
  • COLVIN M, HILTON J: Pharmacology of cyclophosphamide and metabolites. Cancer Treat. Rep. (1981) 65\(Suppl. 3):89–95.
  • BUAHIN KG, JUDY KD, HARTKE C et aL: Controlled release of 4-hydroperoxycyclophosphamide from the fatty acid dimer-sebacic acid copolymer. Polym. Adv. Technol. (1993) 3:311.
  • RECHT LD, GLANTZ MJ, MEITNER P et aL: Unexpected in vitro chemosensitivity of malignant gliomas to 4-hydroxyperoxycyclophosphamide (4-HC). j Neurooncol. (1998) 36(3):201–208.
  • GOODMAN LS, HARDMAN JG, LIMBIRD LE, GILMAN AG: Goodman and Gilman's The Pharmacological Basis of Therapeutics. Goodman LS, Hardman JG, Limbird LE, Gilman AG (Eds), McGraw-Hill, New York, NY, USA (2001):xxvii, 2148, [2141] fold leaf of plates.
  • BOISDRON-CELLE M, MENEI P, BENOIT JP: Preparation and characterization of 5-fluorouracil-loaded microparticles as biodegradable anticancer drug carriers. J. Pharm. PharmacoL (1995) 47(2):108–114.
  • MENEI P, BOISDRON-CELLE M, CROUE A, GUY G, BENOIT JP: Effect of stereotactic implantation of biodegradable 5-fluorouracil-loaded microspheres in healthy and C6 glioma-bearing rats. Neurosurgery (1996) 39(1):117–124.
  • FOURNIER E, PASSIRANI C, VONARBOURG A et al.: Therapeutic efficacy study of novel 5-FU-loaded PMM 2.1.2-based microspheres on C6 glioma. Int. J. Pharm. (2003) 268(1–2):31–35.
  • FOURNIER E, PASSIRANI C, MONTERO-MENEI Get al.: Therapeutic effectiveness of novel 5-fluorouracil-loaded poly(methylidene malonate 2.1.2)-based microspheres on F98 glioma-bearing rats. Cancer (2003) 97(11):2822–2829.
  • LEMAIRE L, ROULLIN VG, FRANCONI F et al.: Therapeutic efficacy of 5-fluorouracil-loaded microspheres on rat glioma: a magnetic resonance imaging study. NMR Biomed. (2001) 14(61:360–366.
  • MENEI P, JADAUD E, FAISANT N et al.: Stereotaxic implantation of 5-fluorouracil-releasing microspheres in malignant glioma. Cancer (2004) 100(2):405–410.
  • MENEI P, VENTER MC, GAMELIN E et al.: Local and sustained delivery of 5-fluorouracil from biodegradable microspheres for the radiosensitization of glioblastoma: a pilot study. Cancer (1999) 86(2):325–330.
  • UN SY, CHENG LF, LUI WY, CHEN CF, HAN SH: Tumoricidal effect of controlled-release polymeric needle devices containing adriamycin HC1 in tumor-bearing mice. Biomater. Art-if Cells Artif Organs (1989) 17(2):189–203.
  • WATTS MC, LESNIAK MS, BURKE M, SAMDANI AF, TYLER BM, BREM H: Controlled release of adriamycin in the treatment of malignant glioma (Poster). American Association of Neurological Surgeons Annual Meeting. Denver, CO, USA (1997).
  • GAYNON PS, ETTINGER LJ, BAUM ES, SIEGEL SE, KRAILO MD, HAMMOND GD: Carboplatin in childhood brain tumors. A Children's Cancer Study Group Phase II trial. Cancer (1990) 66(12):2465–2469.
  • HANNIGAN EV, GREENS, ALBERTS DS, O'TOOLE R, SURWIT E: Results of a Southwest Oncology Group Phase III trial of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide in advanced ovarian cancer. Oncology (1993) 50\(Suppl. 2):2–9.
  • DOZ F, BERENS ME, DOUGHERTY DV ROSENBLUM ML: Comparison of the cytotoxic activities of cisplatin and carboplatin against glioma cell lines at pharmacologically relevant drug exposures. J. NeurooncoL (1991) 11(1):27–35.
  • OLIVI A, GILBERT M, DUNCAN KI,, CORDEN B, LENARTZ D, BREM H: Direct delivery of platinum-based antineoplastics to the central nervous system: a toxicity and ultrastructural study. Cancer Chemother. Pharmacol (1993) 31(0:449–454.
  • UTSUKI T, BREM H, PITHA J et al.: Potentiation of anti-cancer effects of microencapsulated carboplatin by hydroxypropyl a-cyclodextrin. J. Control. Release (1996) 40:251–260.
  • STORM PB, CLATTERBUCK RE, LIU YJ et al.: A surgical technique for safely placing a drug delivery catheter into the pons of primates: preliminary results of carboplatin infusion. Neurosurgery (2003) 52(5):1169–1176; discussion 1176–1167.
  • HSIANG YH, LIU LF: Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res. (1988) 48(7):1722–1726.
  • SLICHENMYER WJ, ROWINSKY EK, DONEHOWER RC, KAUFMANN SH: The current status of camptothecin analogues as antitumor agents. J. Nati Cancer Inst. (1993) 85(4):271–291.
  • WEINGART JD, THOMPSON RC, TYLER B, COLVIN OM, BREM H: Local delivery of the topoisomerase I inhibitor camptothecin sodium prolongs survival in the rat intracranial 9L gliosarcoma model. Int. J. Cancer (1995) 62(5):605–609.
  • STORM PB, MORIARITY JL, TYLER B, BURGER PC, BREM H, WEINGART J: Polymer delivery of camptothecin against 9L gliosarcoma: release, distribution, and efficacy. J. NeurooncoL (2002) 56(3):209–217.
  • SAMPATH P, AMUNDSON E, WALL ME et al.: Camptothecin analogs in malignant gliomas: comparative analysis and characterization. J. Neurosurg. (2003) 98(3):570–577.
  • SENKAL M, TONN JC, SCHONMAYR R et al.: Mitoxantrone-induced DNA strand breaks in cell-cultures of malignant human astrocytoma and glioblastoma tumors. J. NeurooncoL (1997) 32(3):203–208.
  • DIMECO F, LI KW, TYLER BM, WOLF AS, BREM H, OLIVI k Local delivery of mitoxantrone for the treatment of malignant brain tumors in rats. Neurosurg. (2002) 97(5):1173–1178.
  • BOIARDI A, EOLI M, SALMAGGI A et al.: Efficacy of intratumoral delivery of mitoxantrone in recurrent malignant glial tumours. J. Neurooncol (2001) 54(1):39–47.
  • FOLKMAN J: Tumor angiogenesis: therapeutic implications. N Engl J. Med. (1971) 285(21):1182–1186.
  • BREM H, FOLKMAN J: Inhibition of tumor angiogenesis mediated by cartilage. J. Exp. Med. (1975) 141(2):427–439.
  • LANGER R, BREM H, FALTERMAN K, KLEIN M, FOLKMAN J: Isolations of a cartilage factor that inhibits tumor neovascularization. Science (1976) 193(4247):70–72.
  • MOSES MA, SUDHALTER J, LANGER R: Identification of an inhibitor of neovascularization from cartilage. Science (1990) 248(4961):1408–1410.
  • MURRAY JB, ALLISON K, SUDHALTER J, LANGER R: Purification and partial amino acid sequence of a bovine cartilage-derived collagenase inhibitor. Biol. Chem. (1986) 261(9):4154–4159.
  • FOLKMAN J, LANGER R, LINHARDT RJ, HAUDENSCHILD C, TAYLOR S: Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone. Science (1983) 221(4612):719–725.
  • TAIVIARGO RJ, LEONG KW, BREM H: Growth inhibition of the 9L glioma using polymers to release heparin and cortisone acetate. J. NeurooncoL (1990) 9(2):131–138.
  • TAIVIARGO RJ, BOK RA, BREM H: Angiogenesis inhibition by minocycline. Cancer Res. (1991) 51(2):672–675.
  • WEINGART JD, SIPOS EP, BREM H: The role of minocycline in the treatment of intracranial 9L glioma. J. Neurosurg (1995) 82(4):635–640.
  • FRAZIER JL, WANG PP, CASED et al.: Local delivery of minocycline and systemic BCNU have synergistic activity in the treatment of intracranial glioma. Neuroona. (2003) 64(3):203–209.
  • EWEND MG, THOMPSON RC, ANDERSON R et al.: Intracranial paracrine interleukin-2 therapy stimulates prolonged antitumor immunity that extends outside the central nervous system. Immunother. (2000) 23(4):438–448.
  • THOMPSON RC, PARDOLL DM, JAFFEE EM et al.: Systemic and local paracrine cytokine therapies using transduced tumor cells are synergistic in treating intracranial tumors. J. Immunother. Emphasis Tumor Immunol. (1996) 19(6):405–413.
  • HANES J, SILLS A, ZHAO Z et al.: Controlled local delivery of interleukin-2 by biodegradable polymers protects animals from experimental brain tumors and liver tumors. Pharm. Res. (2001) 18(7):899–906.
  • DIMECO F, RHINES LD, HANES J et al.: Paracrine delivery of IL-12 against intracranial 9L gliosarcoma in rats. J. Neurosurg (2000) 92(3):419–427.
  • SAMPATH P, HANES J, DIMECO F et al.: Paracrine immunotherapy with interleukin-2 and local chemotherapy is synergistic in the treatment of experimental brain tumors. Cancer Res. (1999) 59(9):2107–2114.
  • RHINES LD, SAMPATH P, DIMECO F et al.: Local immunotherapy with interleukin-2 delivered from biodegradable polymer microspheres combined with interstitial chemotherapy: a novel treatment for experimental malignant glioma. Neurosurgery (2003) 52(4):872–879; discussion 879–880.
  • RICHARDS GRAYSON AC, CHOI IS et al.: Multi-pulse drug delivery from a resorbable polymeric microchip device. Nat. Mater. (2003) 2(11):767–772.
  • SANTINI JT JR, CIMA MJ, LANGER R: A controlled-release microchip. Nature (1999) 397(6717):335–338.
  • WANG PP, FRAZIER J, BREM H: Local drug delivery to the brain. Adv. Drug Deliv. Rev. (2002) 54:987–1013.
  • BOUSSIF O, LEZOUALC'H F, ZANTA MA et al.: A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc. Natl. Acad. Sci. USA (1995) 92(10:7297–7301.
  • DEMENEIX B, BEHR J, BOUSSIF O, ZANTA MA, ABDALLAH B, REMY J: Gene transfer with lipospermines and polyethylenimines. Adv. Drug Deliv. Rev. (1998) 30(1-3):85–95.
  • SUH J, WIRTZ D, HANES J: Efficient active transport of gene nanocarriers to the cell nucleus. Proc. Natl. Acad. Sci. USA (2003) 100(7):3878–3882.
  • ZANTA MA, BOUSSIF O, ADIB A. BEHR JP: In vitro gene delivery to hepatocytes with galactosylated polyethylenimine. Bioconjug. Chem. (1997) 8(0:839–844.
  • SAKHALKAR HS, DALAL MK, SALEM AK et al.: Leukocyte-inspired biodegradable particles that selectively and avidly adhere to inflamed endothelium in vitro and in vivo. Proc. Natl. Acad. Sci. USA (2003) 100(26):15895–15900.

Websites

  • http://www.cbtrus.org/table05.htm Central Brain Tumor Registry of the United States.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.